key: cord-0785582-snmkp73n authors: Rezaie, A.; Melmed, G. Y.; Leite, G.; Mathur, R.; Takakura, W.; Pedraza, I.; Lewis, M.; Murthy, R.; Chaux, G.; Pimentel, M. title: Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study date: 2021-03-08 journal: nan DOI: 10.1101/2021.03.05.21252997 sha: eb1d9cb434aa8af9f5cf0d7b203704ca91a0f252 doc_id: 785582 cord_uid: snmkp73n Background: Promising preclinical experiments show that, under specific and monitored conditions, ultraviolet-A (UVA) exposure reduces certain bacteria, fungi, and viruses including coronavirus-229E without harming mammalian columnar epithelial cells. We aimed to evaluate the safety and effects of UVA therapy administered by a novel device via endotracheal tube in critically ill subjects with SARS-CoV-2 infection. Methods: Five newly intubated mechanically ventilated adults with SARS-CoV-2 infection, with an endotracheal tube size 7.5mm or greater, were treated with UVA for 20 minutes daily for 5 days, and followed for 30 days. Results: Five subjects were enrolled (mean age 56.6yrs, 3 male). At baseline, all subjects scored 9/10 on the WHO clinical severity scale (10=death) with predicted mortality ranging from 21 to 95%. Average log changes in endotracheal viral load from baseline to day 5 and day 6 were -2.41 (range -1.16 to -4.54; Friedman P=0.002) and -3.20 (range -1.20 to -6.77; Friedman P<0.001), respectively. There were no treatment-emergent adverse events. One subject died 17 days after enrollment due to intracranial hemorrhagic complications of anticoagulation while receiving extracorporeal membrane oxygenation. The remaining subjects clinically improved and scored 2, 4, 5, and 7 on the WHO scale at day 30. In these subjects, the slope of viral load reduction during UVA treatment correlated with the slope of improvement in clinical WHO severity score over time (Spearman rho=1, P<0.001). Conclusion: In this first-in-human study, endotracheal UVA therapy under specific and monitored settings, was safe with a significant reduction in respiratory SARS-CoV-2 viral burden over the treatment period. Since the first report of severe acute respiratory syndrome coronavirus-2 (SARS- infection in December 2019, the global quest to find a highly effective modality to treat severe coronavirus disease 2019 (COVID-19) has been disappointing. Direct cytotoxic effects of SARS-CoV-2 along with dysregulated inflammatory responses and secondary respiratory infections continue to inflict substantial morbidity and mortality in severe and critical cases of COVID-19.[1-3] One mechanism to explain SARS-CoV-2 virulence may be through impairment of the mitochondrial antiviral signaling (MAVS) protein, responsible for innate antiviral responses. [4] Externally applied ultraviolet light therapy is an approved treatment for several atopic, inflammatory and dysplastic dermatologic disorders. [5] In preclinical experiments, ultraviolet-A (UVA) exposure under monitored conditions (i.e. specific intensity, peak wavelength, exposure time and distance to target tissue), reduces bacteria, fungi, and viruses including coronavirus-229E but does not harm human (in vitro) or murine (in vivo) columnar epithelial cells. [6] Moreover, UVA exposure of coronavirus-229E transfected human primary tracheal cells led to activation of the MAVS protein, reduction in spike protein, and resumption of cell proliferation similar to uninfected cells, suggesting that UVA may induce a beneficial antiviral state in infected human cells. [6] Using these newly discovered principles, we aimed to investigate the safety and treatment effects of a novel device inserted into the endotracheal tube to deliver UVA and reduce the viral burden of respiratory SARS-CoV-2 in critically ill subjects. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this first-in-human study, we aimed to recruit and treat 5 subjects. The trial protocol (ClinicalTrials.gov number NCT04572399) was approved by the institutional review board of Cedars-Sinai, Los Angeles and was overseen by an independent data and safety monitoring board (DSMB). Subjects' legally authorized representatives provided written informed consent. Inclusion criteria included age over 18 years, positive PCR test result for SARS-CoV-2 on nasal swab, and mechanical ventilation with an endotracheal tube (ETT) inner diameter of ≥ 7.5 mm. Pregnant women were excluded. Subjects received all standard supportive care; concomitant use of any other COVID-19 treatments was permitted. The UVA therapy device (Aytu Biosciences, Englewood, CO) consisted of a 5.4 mm diameter sterile sealed multi-LED UVA light catheter within a protective sheath and endotracheal adaptor, umbilical, and control unit (Fig. S1 ). The UVA catheter adaptor was connected to the ETT using a double-swivel multi-access port (Halyard Health, GA) to maintain a closed-loop system and prevent ambient exposure to exhaled air upon introduction of the catheter into the ETT. Within 24 hours of enrollment, subjects underwent 20 minutes of endotracheal UVA therapy, which was repeated once daily for a total of 5 consecutive days. All subjects received 100% FiO 2 for 30 minutes prior to the procedure (see Supplemental Materials and Methods for protocol). The UVA catheter was inserted to the distal end of the ETT, with concomitant All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Baseline, hospital, and ICU admission-related information including relevant clinical, laboratory, and radiologic data were recorded for all patients until 30 days after enrollment. The World Health Organization (WHO) COVID-19 10-point ordinal severity scale [7] was calculated at enrollment, and on days 15 and 30 following enrollment. SOFA [8] and SAPSIII [9, 10] scores were calculated from the worst values within 24 hours of ICU admission. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The primary endpoint was the change in ET aspirate SARS-CoV-2 viral load from day 0 to the last day of treatment. Secondary outcomes included treatment-emergent adverse events (TEAEs), changes in endotracheal absolute bacterial load, clinical outcomes and laboratory parameters including inflammatory markers, and changes in the WHO COVID-19 10-point ordinal scale of improvement from baseline to day 15 and 30. Freidman test was used to detect differences across daily viral and bacterial loads. One sample ttest was used to analyze changes in inflammatory markers and microbial loads from day 0 to day 1 [11] . Spearman rank-order test was used to assess correlations between the reduction of viral load (log 10 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Between October 30, 2020 and November 28, 2020, 5 subjects were enrolled (mean age 56.6yrs, 3 male). Baseline characteristics of the enrolled subjects are summarized in Table 1 , and a summary of the timeline and key events is presented in Figure 1 . At the time of intubation, all 5 patients were critically ill, with WHO COVID-19 ordinal scale scores of 9 in all subjects, and with SOFA scores predicting a 20-95% mortality rate. All patients received daily 20-minute treatments starting within the first 36 hours following intubation, for 5 days. Baseline and day 6 ET aspirates were taken in all patients except for study subject #1 who was extubated on day 6. Hence, a total of 29 ET aspirates were analyzed. Subjects had elevated viral loads at baseline (range 3.4x10 4 -1.64x10 7 copies/ml) except for study subject 2 who had an undetectable viral load at all time points, demonstrating that virus had cleared since the last nasal swab (Fig. S2 ). There was no significant correlation between symptom onset date and either baseline (Spearman rho=-0.70, p=0.23) or day 6 viral loads (Spearman rho=-0.21, p=0.83). There was a significant reduction of SARS-CoV-2 levels in endotracheal aspirates during UVA treatment. The average log 10 changes in endotracheal viral load from baseline to day 5 and day 6 were -2.41 (range -1.16 to -4.54; Friedman p=0.002) and -3.2 (range -1.2 to -6.77; Friedman p<0.001), respectively (Fig. 2, Fig. S2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Among the secondary outcome measures, quantification of absolute endotracheal bacterial load at baseline ranged from 1x10 3 -1.7x 10 6 CFU/ml and remained statistically unchanged during the UVA treatment sessions (Fig. S3) . The clinical course for each subject is shown in Figure 1 . WHO clinical severity scores improved by an average of 1.6 and 3.6 points on day 15 and day 30, respectively. Excluding subject 2 who had undetectable baseline viral load, WHO severity scores improved by 4.75 points on day 30 (Table S1 ). All subjects survived except study subject 2, who was placed on comfort care following intracranial hemorrhage due to ECMO-associated anticoagulation and died on ICU day 17. Interestingly, there was an association between WHO clinical severity score outcomes and viral reductions during UVA treatment. Improvement in WHO severity scores by day 30 exhibited a positive correlation with the reduction of viral load during UVA therapy (Spearman's rho=1, p<0.001) (Fig. 2c) . Following UVA therapy, there was a significant drop in C-reactive protein (-95.0 ± 48.0 mg/L, p=0.04) within 7 days of enrollment. Observed reductions in interleukin-6 (-258.9 ± 621.4 pg/mL, p=047) and ferritin (-563.6 ± 514.8 ng/mL, p=0.12) did not reach statistical significance (Table S2) . No treatment-emergent adverse events or need for treatment cessation was observed in the study. Oxygen saturations and hemodynamics during all treatment sessions remained stable. None of the subjects experienced pneumothorax, subcutaneous emphysema, or endotracheal tube (ETT) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.05.21252997 doi: medRxiv preprint dislodgment. Adverse events were deemed unrelated to UVA therapy (Table S3) . Two subjects eventually underwent bronchoscopy for tracheostomy tube placement for prolonged intubation which revealed normal looking tracheae without erythema or friability (Fig. S4 ). An independent Data and Safety Monitoring Board did not recommend any changes to the treatment protocol for future planned trials. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The global challenge associated with the COVID-19 pandemic is a bitter reminder that safe and effective therapies are desperately needed to treat resistant and/or novel pathogens. While externally applied UV therapy is commonly used in dermatologic diseases, due to technological limitations and knowledge gaps, internal UV therapy has never previously been performed. In this first-in-human study, endotracheal UVA light appeared safe in critically ill patients with COVID-19. Furthermore, a significant reduction in endotracheal SARS-CoV-2 levels was observed following 5 days of UVA therapy. Finally, the reduction of viral load during UVA treatment correlated with the reduction in the WHO clinical severity scores. Apart from a dysregulated inflammatory response, heightened viral replication has a critical role in pathogenesis of severe and critical COVID-19. There is a significant association between respiratory SARS-CoV-2 load and mortality. [12] In addition, severe cases of COVID-19 exhibit longer duration and a later peak of virus in respiratory samples as compared to mild disease. [13] Aligned with these findings, 4 out of 5 of our subjects had high viral loads in the endotracheal aspirate at baseline ICU care without a significant correlation with the time of symptom onset. In addition, improvement of WHO clinical severity scores by day 30 significantly correlated with the reduction of viral load during UVA therapy. Taken together, these suggest a temporal overlap between the viral replication and hyperinflammatory phases [2] in the disease course of critically ill COVID-19 patients. Hence, these patients may continue to benefit both from viral load reduction and from improvement of the innate immune response to SARS-CoV-2. UVA potentially possesses the ability to provide benefit in both areas. Firstly, we have shown previously that UVA therapy exhibits antiviral effects against positive sense, single-stranded All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.05.21252997 doi: medRxiv preprint 12 RNA viruses including coxsackievirus and coronavirus-229E. [6] Secondly, in vitro UVA exposure led to activation of MAVS protein in virally infected primary human tracheal cells, a pathway that is directly impaired by SARS-CoV-2. Activation of the MAVS protein pathway by UVA exposure in SARS-CoV-2-infected tracheal cells may be a mechanism behind the significant reduction of viral load along the respiratory tract in our study despite only intermittent and localized UVA therapy in the upper airway. As compared to conventional microbial cultures, absolute bacterial load quantified by PCR detects a greater number of bacteria including unculturable and non-viable bacteria yielding higher load of bacteria. We did not detect a significant change in endotracheal aspirate bacterial loads during UV therapy. This is encouraging and is likely due to leveraging a closed-loop system for introduction of the sterile UVA catheter. We previously have shown that UVA reduces several known pathogens linked to ventilator associated pneumonia (VAP) including (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bleeding occurs in approximately 50% of patients undergoing ECMO [15] with intracranial hemorrhage having an 85% risk of mortality. [16] Despite being in a highly critical state, 4 out of 5 subjects survived and had meaningful clinical improvements (Table S1 ). Further trials are needed to elucidate whether UVA therapy can improve clinical outcomes. Our study has several limitations. As this was a first-in-human trial, the sample size was small. Using a novel device in a specific and monitored setting, endotracheal UVA therapy in critically ill subjects is associated with a significant reduction of respiratory SARS-CoV-2 viral load. Viral load reduction correlated with improvements in the WHO severity score by day 30. Finally, to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. patients with detectable viral load at baseline. Freidman test is used to analyze differences across daily viral load measurements. B) Corresponding viral loads (log) for each subject at baseline, day 5 and 6. Average log changes from baseline to day 5 and day 6 were -2.41(relative reduction >99%) and -3.2 (relative reduction >99.9%), respectively. C) The individual slopes of reduction in SARS-CoV-2 loads during UVA therapy correlated with the slopes of reduction in WHO severity score by day 30. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.05.21252997 doi: medRxiv preprint Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer Ultraviolet A light effectively reduces bacteria and viruses including coronavirus Working Group on the Clinical Characterisation and Management of Covid-19 infection (2020) A minimal common outcome measure set for COVID-19 clinical research The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission Using the Student's t-test with extremely small sample sizes SARS-CoV-2 viral load predicts COVID-19 mortality No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review Predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: an observational cohort study Availability of data and materials: All data is available in the main text or the supplementary materials.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.05.21252997 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.05.21252997 doi: medRxiv preprint